These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31021010)

  • 1. Case of severe bullous erythema including intertrigo-like eruptions with angioedema induced by pegylated liposomal doxorubicin.
    Totsuka M; Watanabe Y; Asai C; Takahashi S; Ishikawa H; Takamura N; Hagiwara M; Aihara M
    J Dermatol; 2019 Jun; 46(6):535-539. PubMed ID: 31021010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An intertrigo-like eruption from pegylated liposomal doxorubicin.
    Korver GE; Ronald H; Petersen MJ
    J Drugs Dermatol; 2006 Oct; 5(9):901-2. PubMed ID: 17039658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD).
    Sánchez Henarejos P; Ros Martínez S; Marín Zafra GR; Alonso Romero JL; Navarrete Montoya A
    Clin Transl Oncol; 2009 Jul; 11(7):486-7. PubMed ID: 19574209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intertrigo-like dermatitis with pegylated liposomal doxorubicin: diagnosis and management.
    Najem A; Deregnaucourt D; Ramdane S; Dridba M; Djouba F; Vercambre-Darras S
    J Clin Oncol; 2014 Nov; 32(31):e104-6. PubMed ID: 24550424
    [No Abstract]   [Full Text] [Related]  

  • 5. Malignant intertrigo.
    Liu C; Ko MJ
    CMAJ; 2018 May; 190(19):E595. PubMed ID: 29759966
    [No Abstract]   [Full Text] [Related]  

  • 6. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.
    Kanis M; Kesterson JP; Lele S
    Eur J Gynaecol Oncol; 2009; 30(4):387-8. PubMed ID: 19761128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
    English JC; Toney R; Patterson JW
    J Cutan Pathol; 2003 Oct; 30(9):591-5. PubMed ID: 14507411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striking follicular eruption to pegylated liposomal doxorubicin.
    Dai J; Micheletti R; Rosenbach M; Chu EY
    Am J Dermatopathol; 2014 Jul; 36(7):590-1. PubMed ID: 24614205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
    Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
    Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host-vs.-altered-host eruptions in patients on liposomal doxorubicin.
    Skelton H; Linstrum J; Smith K
    J Cutan Pathol; 2002 Mar; 29(3):148-53. PubMed ID: 11972711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe palmoplantar erythrodysesthesia and intertrigolike eruption induced by polyethylene glycol-coated liposomal doxorubicin.
    Campanelli A; Kerl K; Lübbe J
    J Eur Acad Dermatol Venereol; 2006 Sep; 20(8):1022-4. PubMed ID: 16922969
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
    Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
    Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
    Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
    Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.
    Mangana J; Zipser MC; Conrad C; Oberholzer PA; Cozzio A; Knuth A; French LE; Dummer R
    Eur J Dermatol; 2008; 18(5):566-70. PubMed ID: 18693162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.
    Herzog TJ; Kutarska E; Bidzińsk M; Symanowski J; Nguyen B; Rangwala RA; Naumann RW
    Int J Gynecol Cancer; 2016 Nov; 26(9):1580-1585. PubMed ID: 27654255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
    Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
    Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
    Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.
    Molpus KL; Anderson LB; Craig CL; Puleo JG
    Gynecol Oncol; 2004 May; 93(2):513-6. PubMed ID: 15099971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
    Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
    Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.